Veristrat

VeriStrat® is a test aiming at predicting benefit from cancer treatment by EGFR inhibitors. It is a serum/plasma proteomic test developed using matrix-assisted laser desorption/ionization (MALDI) mass spectrometry. VeriStrat was developed by Biodesix, Inc., a molecular diagnostics company based in Boulder, CO, USA.

The VeriStrat algorithm has been interrogated retrospectively and prospectively in samples from randomised trials, such as the PROSE study, confirming the prognostic information associated with the molecular signature. In addition, the test appeared to be predictive of erlotinib impact on survival, as only "VeriStrat Good patients" benefited from such a treatment. Additional studies should confirm and further define its role in predicting EGFR inhibitors benefit.[1]

References

  1. ↑ Molina-Pinelo, S; Pastor, M. D.; Paz-Ares, L (2014). "Veri Strat: A prognostic and/or predictive biomarker for advanced lung cancer patients?". Expert Review of Respiratory Medicine 8 (1): 1–4. doi:10.1586/17476348.2014.861744. PMID 24308656.


This article is issued from Wikipedia - version of the Monday, October 05, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.